The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
 
Maria Catherine Pietanza
Honoraria - Celgene; Genentech
Consulting or Advisory Role - Celgene; Genentech
Speakers' Bureau - PER; Quintiles
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); OncoMed (Inst); Stem CentRx (Inst)
 
Alexander I. Spira
No Relationships to Disclose
 
Robert M. Jotte
No Relationships to Disclose
 
Shirish M. Gadgeel
No Relationships to Disclose
 
Alain C. Mita
No Relationships to Disclose
 
Lowell L. Hart
No Relationships to Disclose
 
W Larry Gluck
No Relationships to Disclose
 
Anne C. Chiang
Honoraria - Genentech
Consulting or Advisory Role - Genentech/Roche
Research Funding - Boehringer Ingelheim; Millennium; OncoMed; Onyx
 
Stephen V. Liu
Consulting or Advisory Role - Biodesix; Genentech; Perthera
 
Ann M. Kapoun
Employment - OncoMed
Stock and Other Ownership Interests - OncoMed
 
Lu Xu
Employment - OncoMed
Stock and Other Ownership Interests - OncoMed
 
Dawn Hill
Employment - OncoMed
Stock and Other Ownership Interests - OncoMed
 
Jakob Dupont
Employment - OncoMed
Stock and Other Ownership Interests - OncoMed
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
 
Lei Zhou
Consulting or Advisory Role - OncoMed